Studies a PSMA PET scan to help find and track prostate cancer
Looks at a PSMA PET scan in adults with prostate cancer at all stages.
Plain-language title generated from the registry record
Registry title: Monocentric Observational Study on the Diagnostic and Prognostic Role of 18F-PSMA PET (PET/CT and PET/MR) in Prostate Cancer
Key facts
- Where
- Milan, ItalySee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adult men with proven prostate cancer who need a PET scan with 18F-PSMA to check or re-check how far the cancer has spread.
- Age
- 18 years or older
- Sex
- Men only
- Disease stage
- Prostate cancer confirmed by tissue examination, at staging or restaging (all stages of the disease)
Main reasons for not taking part
- Medical conditions that do not allow PET images to be taken
- Allergic reaction to iodinated contrast medium
- Creatinine level above 2mg/dL (177 µmol/L)
Read by machine on 12 November 2026.
Where in Italy
- IRCMilan, ItalyContact: Arturo ChitiTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- IRCCS San Raffaele
- Trial code
- NCT06167629
- Record updated
- 12 December 2023
- Original description
The general objective of this retrospective and prospective study is to evaluate the diagnostic and prognostic role of a quantitative analysis of PET images with 18F-PSMA in all stages of the disease in patients with prostate cancer. To this end, both imaging parameters commonly used in clinical practice and the contribution of radiomic features will be investigated. The latter are quantitative features extracted from biomedical images, and are believed to be able to provide information, otherwise impossible to investigate, useful for the characterization of various pathologies. This methodology is very promising, but also recent and therefore little studied and standardized. Our objective is also to investigate how to optimize it from a purely methodological point of view.Read full original descriptionShow less
Monocentric Observational Study on the Diagnostic and Prognostic Role of 18F-PSMA PET (PET/CT and PET/MR) in Prostate Cancer
The general objective of this retrospective and prospective study is to evaluate the diagnostic and prognostic role of a quantitative analysis of PET images with 18F-PSMA in all stages of the disease in patients with prostate cancer. To this end, both imaging parameters commonly used in clinical practice and the contribution of radiomic features will be investigated. The latter are quantitative features extracted from biomedical images, and are believed to be able to provide information, otherwise impossible to investigate, useful for the characterization of various pathologies. This methodology is very promising, but also recent and therefore little studied and standardized. Our objective is also to investigate how to optimize it from a purely methodological point of view.
Inclusion: adult male patients; patients with histopathological diagnosis of prostate cancer undergoing staging or restaging; patients with clinical indication for PET examination with 18 F-PSMA.
Exclusion: medical conditions that do not allow the acquisition of PET images; allergic reactions to iodinated contrast medium or creatinine levels >2mg/dL.